Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Common Equity (2018 - 2025)

Revolution Medicines has reported Common Equity over the past 8 years, most recently at $1.6 billion for Q4 2025.

  • Quarterly results put Common Equity at $1.6 billion for Q4 2025, down 27.98% from a year ago — trailing twelve months through Dec 2025 was $1.6 billion (down 27.98% YoY), and the annual figure for FY2025 was $1.6 billion, down 27.98%.
  • Common Equity for Q4 2025 was $1.6 billion at Revolution Medicines, up from $1.6 billion in the prior quarter.
  • Over the last five years, Common Equity for RVMD hit a ceiling of $2.3 billion in Q4 2024 and a floor of $498.8 million in Q2 2022.
  • Median Common Equity over the past 5 years was $941.5 million (2023), compared with a mean of $1.2 billion.
  • Biggest five-year swings in Common Equity: surged 166.52% in 2023 and later decreased 27.98% in 2025.
  • Revolution Medicines' Common Equity stood at $602.6 million in 2021, then rose by 13.71% to $685.2 million in 2022, then surged by 166.52% to $1.8 billion in 2023, then grew by 24.04% to $2.3 billion in 2024, then decreased by 27.98% to $1.6 billion in 2025.
  • The last three reported values for Common Equity were $1.6 billion (Q4 2025), $1.6 billion (Q3 2025), and $1.9 billion (Q2 2025) per Business Quant data.